- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07739953
Development and Clinical Application of ApoC3 Protein as a Predictive Biomarker for Insulin Resistance in Polycystic Ovary Syndrome
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiesteder
-
-
-
Guangzhou, Kina
- Guangdong Women and Children Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
This study included PCOS patients diagnosed according to the 2003 Rotterdam criteria (at least 2 of: oligo/anovulation, clinical/biochemical hyperandrogenism, or polycystic ovaries on ultrasound). Patients were divided into two groups:
PCOS-IR group: met PCOS criteria plus at least one of: HOMA-IR ≥ 2.5, fasting insulin ≥ 15 μIU/mL, or diagnosed IGT/T2DM.
PCOS-non-IR group: met PCOS criteria with HOMA-IR < 2.5 and no glucose metabolism abnormalities.
Exclusion criteria: other endocrine disorders, medication use, severe systemic diseases, pregnancy/lactation, or poor sample quality.
Beskrivelse
I. Diagnostic Criteria
The 2003 Rotterdam diagnostic criteria for PCOS jointly established by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM):
Clinical and/or biochemical signs of hyperandrogenism; Oligo-ovulation or anovulation; Ultrasound findings: ovarian volume ≥ 10 mL, and/or > 12 follicles with a diameter of 2-9 mm in a single section.
A diagnosis of PCOS can be established when at least two of the following three criteria are met: ovarian dysfunction, hyperandrogenism, and polycystic ovarian morphology on ultrasound.
II. Inclusion and Exclusion Criteria
PCOS with Insulin Resistance (PCOS-IR)
Inclusion Criteria:
Meets the 2003 Rotterdam diagnostic criteria for PCOS (at least 2 of the following 3 items):
① Oligo-ovulation or anovulation;
② Clinical or biochemical signs of hyperandrogenism;
③ Polycystic ovaries on ultrasound (unilateral or ovarian volume ≥ 10 mL).
Insulin resistance (IR), meeting at least 1 of the following 3 criteria:
① HOMA-IR ≥ 2.5;
② Fasting insulin ≥ 15 μIU/mL;
③ Diagnosed impaired glucose tolerance (IGT) or type 2 diabetes mellitus (T2DM).
Exclusion Criteria:
Other endocrine disorders; Medication effects; Severe systemic diseases; Special physiological conditions (e.g., pregnancy, lactation); Poor sample quality.
- PCOS without Insulin Resistance (PCOS-non-IR)
Inclusion Criteria:
Meets the PCOS diagnostic criteria (as above), with HOMA-IR < 2.5 and no glucose metabolism abnormalities.
Exclusion Criteria: Same as above.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
adverse pregnancy outcomes and long-term complications such as type 2 diabetes mellitus
Tidsramme: 1year
|
1year
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Neoplasmer
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Kønssygdomme, kvindelige
- Ovariesygdomme
- Adnexale sygdomme
- Gonadale lidelser
- Ovariecyster
- Cyster
- Polycystisk ovariesyndrom
- Undersøgelsesteknikker
- Metoder
- Observation
Andre undersøgelses-id-numre
- GuangdongWCH-Li Li4
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .